S100A8/A9 in COVID-19 pathogenesis: Impact on clinical outcomes.
S100A8/A9 in COVID-19 pathogenesis: Impact on clinical outcomes.
复制标题
DOI：
10.1016/j.cytogfr.2021.10.004
复制
发表时间：
2022-03
影响因子：
13
通讯作者：
Khader SA
中科院分区：
文献类型：
--
作者：
Mellett L;Khader SA
冠状病毒病2019年(新冠肺炎)具有广泛的临床表现，突显出需要特定的诊断工具来预测疾病严重程度和改善患者预后。最近，钙保护素(S100A8/A9)被认为是一种潜在的新冠肺炎生物标志物，因为血清S100A8/A9水平升高与新冠肺炎危重病例相关，并可区分轻度和重度疾病状态。S100A8/A9是一种警报蛋白，在感染过程中介导宿主的促炎反应，并被认为调节细胞因子风暴；这是致命新冠肺炎病例的标志。然而，S100A8/A9是否是新冠肺炎的真正生物标志物仍有待确定。S100A8/A9广泛与多种炎症状态有关，如囊性纤维化(CF)和慢性阻塞性肺疾病(COPD)，以及包括结核病和流感在内的肺部传染病。因此，了解S100A8/A9水平如何与炎症性疾病期间的免疫反应相关，对于评估其作为潜在的新冠肺炎生物标志物的可行性是必要的。该综述将概述S100A8/A9在感染过程中的保护和有害作用，综述S100A8/A9在新冠肺炎发病机制中的最新研究成果，并强调其作为诊断生物标志物和治疗包括新冠肺炎在内的肺部传染病的潜在靶点。
Coronavirus disease 2019 (COVID-19) has a broad range of clinical manifestations, highlighting the need for specific diagnostic tools to predict disease severity and improve patient prognosis. Recently, calprotectin (S100A8/A9) has been proposed as a potential biomarker for COVID-19, as elevated serum S100A8/A9 levels are associated with critical COVID-19 cases and can distinguish between mild and severe disease states. S100A8/A9 is an alarmin that mediates host proinflammatory responses during infection and it has been postulated that S100A8/A9 modulates the cytokine storm; the hallmark of fatal COVID-19 cases. However, it has yet to be determined if S100A8/A9 is a bona-fide biomarker for COVID-19. S100A8/A9 is widely implicated in a variety of inflammatory conditions, such as cystic fibrosis (CF) and chronic obstructive pulmonary disorder (COPD), as well as pulmonary infectious diseases, including tuberculosis and influenza. Therefore, understanding how S100A8/A9 levels correlate with immune responses during inflammatory diseases is necessary to evaluate its candidacy as a potential COVID-19 biomarker. This review will outline the protective and detrimental roles of S100A8/A9 during infection, summarize the recent findings detailing the contributions of S100A8/A9 to COVID-19 pathogenesis, and highlight its potential as diagnostic biomarker and a therapeutic target for pulmonary infectious diseases, including COVID-19.
登录
查看更多内容
影响因子：
8.1
作者：
Hojyo S;Uchida M;Tanaka K;Hasebe R;Tanaka Y;Murakami M;Hirano T
通讯作者：
Hirano T
DOI：
10.1164/rccm.201304-0803oc
发表时间：
2013-11-01
影响因子：
24.7
作者：
Gopal, Radha;Monin, Leticia;Khader, Shabaana A.
通讯作者：
Khader, Shabaana A.
影响因子：
30.3
作者：
Guo Q;Zhao Y;Li J;Liu J;Yang X;Guo X;Kuang M;Xia H;Zhang Z;Cao L;Luo Y;Bao L;Wang X;Wei X;Deng W;Wang N;Chen L;Chen J;Zhu H;Gao R;Qin C;Wang X;You F
通讯作者：
You F
DOI：
10.1038/nri2873
发表时间：
2010-12
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
通讯作者：
--
DOI：
10.1016/j.meegid.2020.104587
发表时间：
2020-11
期刊：
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
影响因子：
--
作者：
Bhattacharya M;Sharma AR;Mallick B;Sharma G;Lee SS;Chakraborty C
通讯作者：
Chakraborty C